KPV

Three amino acids that carry nearly all of α-MSH’s anti-inflammatory power, and unusually for a peptide, it works by mouth.

Evidence: ELab & animal what's this?
Grade E. Consistent animal data, especially for gut inflammation; limited human data.
Also known as: Lys-Pro-Val · KPV tripeptide
Class: Synthetic tripeptide, the C-terminal end of α-MSH

The 30-second version

WhatThe last three amino acids of α-MSH, without its skin-darkening or hormonal effects.

Why people use itGut inflammation and barrier support, inflammatory skin, and general recovery.

The honest catchThe human trials that would confirm gut and skin benefits haven’t been done.

What it is

α-MSH is a natural hormone involved in pigmentation, appetite and immune signalling. In the 1980s and ’90s researchers found its anti-inflammatory effect sits almost entirely in its last three amino acids, Lys-Pro-Val. On its own, KPV calmed inflammation in mice about as well as a corticosteroid. It avoids the melanocortin receptors that melanotan peptides use, so it doesn’t tan the skin. KPV is the anti-inflammatory ingredient that turns GLOW into KLOW.

How it works

Gets in. In the gut, the PepT1 transporter in the intestinal lining pulls KPV into cells.

NF-κB off. Blocks the master switch for inflammation inside the cell.

Fewer cytokines. Less TNF-α, IL-1β and IL-6 are produced.

Barrier. Gut and skin epithelium tighten and recover.

Extras. Some antimicrobial activity, and stabilises mast cells.

Proline and valine resist digestive enzymes, and PepT1 carries it across the gut wall, so oral KPV can reach the intestine intact. That makes oral dosing a real option for gut use.

What the research shows

In animals: in colitis and IBD models, KPV cut intestinal inflammation substantially (roughly in half in some studies), protected the mucosal barrier and sped healing of damaged lining. PepT1 uptake was clearly demonstrated². It also calmed eczema, psoriasis and dermatitis models. The broader α-MSH tripeptide literature is consistent^1,3. In people: limited. Human use rests on this preclinical base and community experience.

A clean, well-tolerated anti-inflammatory with strong animal gut data and thin human proof.

Evidence at a glance

Use	Grade	Best evidence	Main gap	Read
Gut inflammation, IBD	ELab & animal	Inflammation cut, barrier protected²	No human trials	Strong preclinical
Mechanism	ELab & animal	Blocks NF-κB; lowers TNF, IL-6^1,3	Cell level	Well mapped
Skin inflammation	ELab & animal	Calmed eczema and psoriasis models	Animal	Supportive
Human outcomes	DCommunity use	Reported gut and skin benefit	No RCT	Promising

Dosing: what has been reported

Not a recommendation. These figures describe what was studied or what circulates in practice, kept separate so you can see how solid each one is. Speak with a qualified clinician before acting on any of it.

Setting	Figure	Route	Grade
Published human	No established dose	—	—
Community, gut	200–500 mcg/day, often enteric-coated capsules	Oral	D
Community, systemic	200–500 mcg/day	Subcutaneous	D
Community, skin	Per formulation, daily	Topical	D

Match the route to the target. Some people go up to 1,000 mcg a day, but there’s no better support for that than for the standard range. Courses usually run several weeks.

Preparing & storing

For injection, reconstitute with bacteriostatic water and refrigerate. It’s small and enzyme-resistant, so it’s relatively stable.

Reported side effects

Most users report little or nothing
Mild injection-site redness
Occasional digestive upset with oral use
Rare mild headache or fatigue
No pigmentation change

Symptom tracking is the main read. hs-CRP or faecal calprotectin can add an objective measure for gut use.

Who should avoid it

Pregnancy and breastfeeding
Active serious infection: get medical input first
Never as a replacement for prescribed IBD or skin treatment

Regulatory status checked Oct 2026

Body	Status	Detail
FDA (US)	Not approved	Under compounding review in 2026; research use only.
EMA (EU)	Not approved	No marketing authorisation.
CDSCO (India)	Not approved	No approval identified.
WADA	Not named	Low doping relevance; S0 could apply to an unapproved injectable.

The NexGen read

The quiet anti-inflammatory

KPV is one of the best-tolerated peptides in this guide, and its oral route makes it unusually practical for the gut. Treat it as support alongside proper care, not as a cure.

References

Brzoska T, Luger TA, Maaser C, et al. α-MSH and related tripeptides: anti-inflammatory and protective effects. Endocr Rev. 2008;29(5):581–602.
Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178.
Catania A, Rajora N, Capsoni F, et al. α-MSH has specific receptors on neutrophils and reduces chemotaxis in vitro. Peptides. 1996;17(4):675–679.